Molecular and Immunologic Analysis of the Pathobiology of Human Anthrax
人类炭疽病病理学的分子和免疫学分析
基本信息
- 批准号:10213407
- 负责人:
- 金额:$ 47.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVARID3A geneAdult Respiratory Distress SyndromeAgeAnthrax diseaseAntiviral AgentsAutopsyBiologicalBiological MarkersBiologyCOVID-19CellsCessation of lifeCharacteristicsChronicClinicalClinical Course of DiseaseClinical DataClinical DistributionCohort StudiesCollaborationsCoronavirusDataDecision MakingDeteriorationDiabetes MellitusDiseaseEnrollmentEpigenetic ProcessFailureFundingGoalsGrantHealth SciencesHeart DiseasesHospitalizationHumanImmuneImmune responseImmune systemImmunologicsImmunophenotypingIndividualInfectionInnate Immune ResponseInnate Immune SystemInpatientsInstitutionInterferon-alphaInterleukin-6InterventionKnowledgeLaboratoriesLungLung diseasesMeasuresMedicalMolecularMolecular ProfilingOklahomaOutcomePatient CarePatientsPredispositionPreventionProcessProteinsRecoveryResearchResearch PersonnelResourcesRiskSamplingSecondary toSiteSyndromeSystemTalentsTestingTherapeutic InterventionTherapeutic TrialsUnited States National Institutes of HealthUniversitiesViralViral Load resultViral PneumoniaVirusclinical careclinical predictorsclinical riskcohortcytokine release syndromedensityexperienceexperimental studyfollow-upinsightmolecular markerneutrophilnovelnovel coronavirusparent grantpathogenpneumocyteprotein expressionrecruitresponsescreeningtargeted treatmenttherapeutic vaccinetherapy developmentvaccine developmentvirus host interaction
项目摘要
Summary/Abstract
Innate immune dysregulation causes the severe effects of SARS-CoV-2 infections. The unique ways this novel,
emergent pathogen evades and co-opts the host immune response is not known. A better understanding of the
virus-host interactions regulating the innate immune response in SARS-CoV-2 infections will provide a basis for
therapeutic interventions and vaccine development. The Immunophenotyping Assessment in a COVID-19
Cohort (IMPACC) study coordinates a national, multi-institution consortium, collecting detailed clinical data and
biologic samples from hospitalized COVID-19 infected individuals, with the goal of identifying immune
signatures/molecular biomarkers associated with clinical disease course, to allow the prioritization of clinical
interventions and decision making. This supplement supports the University of Oklahoma Health Sciences
Centers’ participation in IMPACC to facilitate screening and enrollment of inpatients with COVID-19. It also
examines the hypothesis that that ARID3a protein expression in low-density neutrophils is associated with the
proinflammatory state that occurs during COVID-19 infection. The proposed supplement research is within the
scope of the parent grant U19AI062629, Molecular and Immunologic Analysis of the Pathobiology of Human
Anthrax. Here, we outline the process by which we will recruit, enroll and retain subjects for the IMPACC study
at our health sciences center, and obtain the clinical information and laboratory samples required. Our group
has previously collected the same samples and similar clinical information as part of a previous NIH therapeutic
trial, IRC005, and we were a top enroller (3rd of ~40 sites participating) in that study. The additional hypothesis-
driven experimental low-density neutrophil study will be performed in collaboration with a talented and
experienced investigator, and will exploit the corresponding clinical data that will be collected as part of the
IMPACC study. Thus, the proposed study will not only help the IMPACC study towards a successful conclusion,
but also generate new insights into the basic biology of coronavirus-host interactions and may reveal a novel
mechanism for the differences in the innate immune responses to SARS-CoV-2 between those that recover from
disease requiring hospitalization, and those that progress to poor outcomes or delayed recovery.
摘要/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kenneth Mark Coggeshall其他文献
Kenneth Mark Coggeshall的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kenneth Mark Coggeshall', 18)}}的其他基金
Molecular and Immunologic Analysis of the Pathobiology of Human Anthrax
人类炭疽病病理学的分子和免疫学分析
- 批准号:
10239273 - 财政年份:2020
- 资助金额:
$ 47.65万 - 项目类别:
Molecular and Immunologic Analysis of the Pathobiology of Human Anthrax
人类炭疽病病理学的分子和免疫学分析
- 批准号:
10264258 - 财政年份:2020
- 资助金额:
$ 47.65万 - 项目类别:
Development of a mouse model of peptidoglycan-induced pathology
肽聚糖诱导病理学小鼠模型的开发
- 批准号:
8898008 - 财政年份:2014
- 资助金额:
$ 47.65万 - 项目类别:
B. anthracis Peptidoglycan as a Pro-inflammatory Agent in Anthrax Pathogenesis
B. 炭疽杆菌肽聚糖作为炭疽发病机制中的促炎剂
- 批准号:
7695608 - 财政年份:2009
- 资助金额:
$ 47.65万 - 项目类别:














{{item.name}}会员




